title: Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
abstract: Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients' poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
authors.affiliation: Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Jaipur, Rajasthan 302 023, India. jawedpharma@gmail.com.
authors.forename: Mohamed Jawed
authors.initials: MJ
authors.lastname: Ahsan
authors.forename: Mohammad Yousuf
authors.initials: MY
authors.lastname: Ansari
authors.forename: Sabina
authors.initials: S
authors.lastname: Yasmin
authors.forename: Surender Singh
authors.initials: SS
authors.lastname: Jadav
authors.forename: Pradeep
authors.initials: P
authors.lastname: Kumar
authors.forename: Shiv Kumar
authors.initials: SK
authors.lastname: Garg
authors.forename: Ajay
authors.initials: A
authors.lastname: Aseri
authors.forename: Habibullah
authors.initials: H
authors.lastname: Khalilullah
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D064687:Diarylquinolines / Q000627:therapeutic use / Q000633:toxicity; D023801:Directly Observed Therapy; D055808:Drug Discovery; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012293:Rifampin / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity; D014376:Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D032581:Tuberculosis Vaccines / Q000627:therapeutic use
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; D032581:Tuberculosis Vaccines; C493870:bedaquiline; D012293:Rifampin; C018421:rifapentine